

GALANTAS GOLD CORPORATION

Condensed Interim Consolidated Financial Statements (Expressed in Canadian Dollars)

> (Unaudited) Three and Six Months Ended June 30, 2021

NOTICE TO READER

The accompanying unaudited condensed interim consolidated financial statements of Galantas Gold Corporation (the "Company") have been prepared by and are the responsibility of management. The unaudited condensed interim consolidated financial statements have not been reviewed by the Company's auditors.

Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian Dollars) (Unaudited)

	As at June 30, 2021	D	As at December 31, 2020
ASSETS			
Current assets			
Cash and cash equivalents	\$ 6,142,477	\$	612,094
Accounts receivable and prepaid expenses (note 4)	751,128		594,960
Inventories (note 5)	143,858		81,169
Total current assets	7,037,463		1,288,223
Non-current assets			
Property, plant and equipment (note 6)	21,886,598		21,158,103
Long-term deposit (note 8)	513,780		521,430
Exploration and evaluation assets (note 7)	827,182		750,741
Total non-current assets	23,227,560		22,430,274
Total assets	\$ 30,265,023	\$	23,718,497
EQUITY AND LIABILITIES			
Current liabilities			
Accounts payable and other liabilities (notes 9 and 16)	\$ 2,390,715	\$	1,350,142
Current portion of financing facilities (note 10)	-		2,186,272
Due to related parties (note 14)	100,842		5,461,893
Total current liabilities	2,491,557		8,998,307
Non-current liabilities			
Non-current portion of financing facilities (note 10)	4,601,474		-
Due to related parties (note 14)	2,577,137		-
Decommissioning liability (note 8)	594,906		598,275
Total non-current liabilities	7,773,517		598,275
Total liabilities	10,265,074		9,596,582
Equity			
Share capital (note 11(a)(b))	57,559,598		52,933,594
Reserves	14,514,682		9,734,121
Deficit	(52,074,331)		(48,545,800)
Total equity	19,999,949		14,121,915
Total equity and liabilities	\$ 30,265,023	\$	23,718,497

The notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

Going concern (note 1) Incorporation and nature of operations (note 2) Contingency (note 16) Events after the reporting period (note 17)



Galantas Gold Corporation Condensed Interim Consolidated Statements of Loss

(Expressed in Canadian Dollars)

(Unaudited)

	Three Months June 30,				nths Ended ne 30,			
		2021		2020		2021		2020
Revenues								
Sales of concentrate (note 13)	\$	-	\$	-	\$	-	\$	-
Cost and expenses of operations								
Cost of sales		61,333		31,239		107,481		67,075
Depreciation (note 6)		87,088		84,391		159,153		173,118
		148,421		115,630		266,634		240,193
Loss before general administrative and other								
expenses		(148,421)		(115,630)		(266,634)		(240,193)
Concerci odministrativo oversos								
General administrative expenses Management and administration wages (note 14)		81,951		143,114		226,034		284,336
Other operating expenses		39,835		57,360		72,415		151,420
Accounting and corporate		73,273		15,109		88,457		29,253
Legal and audit		73,273 31,464		28,834		80,437 80,637		70,952
Stock-based compensation (note 11(d))		1,230,510		20,034 12,064		1,235,141		(4,224)
Shareholder communication and investor relations		116,888		45,882		176,741		92,958
		•						
Transfer agent Director fees (note 14)		9,046 15,500		26,738 8,500		11,907 24,000		54,474 14,750
General office		7,770		8,500 2,776		24,000 11,339		5,489
-		•		,				
Accretion expenses (notes 8 and 10)		27,856		164,797		132,416		310,918
Loan interest and bank charges less deposit		00 700		145 550		400.000		207 460
interest (notes 10 and 14)		80,780		145,553		160,883		297,169
Financing costs (note 10)		1,004,182		-		1,004,182		-
		2,719,055		650,727		3,224,152		1,307,495
Other expenses		04 000		05 704		07 745		(75.000)
Foreign exchange loss (gain)		21,092		25,784		37,745		(75,232)
		21,092		25,784		37,745		(75,232)
Net loss for the period	\$	(2,888,568)	\$	(792,141)	\$	(3,528,531)	\$ ((1,472,456)
Basic and diluted net loss per share (note 12)	\$	(0.05)		(0.02)	\$	(0.07)		(0.05)
Weighted average number of common shares		, <i>,</i> ,		· · · · · · · · · · · · · · · · · · ·				
outstanding - basic and diluted		60,494,975		32,321,472		53,501,436	3	32,321,472

The notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.



Galantas Gold Corporation Condensed Interim Consolidated Statements of Comprehensive Loss (Expressed in Canadian Dollars)

(Unaudited)

	Three Mo June		Six Months Ended June 30,
	2021	2020	2021 2020
Net loss for the period	\$ (2,888,568) \$	(792,141) \$	(3,528,531) \$ (1,472,456)
Other comprehensive loss Items that will be reclassified subsequently to profit or loss Exchange differences on translating foreign			
operations	(198,369)	(670,131)	(295,294) (287,422)
Total comprehensive loss	\$ (3,086,937) \$	(1,462,272) \$	(3,823,825) \$ (1,759,878)

The notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.



Galantas Gold Corporation Condensed Interim Consolidated Statements of Cash Flows (Expressed in Canadian Dollars)

(Unaudited)

2021 2020 Operating activities Net loss for the period \$ (3,528,531) \$ (1,472,456) Adjustment for: 159,153 173,118 Stock-based compensation (note 11(d)) 1,235,141 (4,224) Accrued interest (notes 10 and 14) 158,239 295,889 Foreign exchange loss 344,243 53,274 Accrued interest (notes 10) 1,004,182 - Non-cash working capital items: - Accounts payable and openaid expenses (168,600) 26,588 Inventories (142,7718) - - - - Accounts payable and other liabilities (24,233) (422,7718) - <t< th=""><th></th><th></th><th></th><th>ths Ende าe 30,</th><th colspan="2">ded</th></t<>				ths Ende าe 30,	ded	
Net loss for the period \$ (3,528,531) \$ (1,472,456) Adjustment for: Depreciation (note 6) 159,153 173,118 Stock-based compensation (note 11(d)) 1,235,141 (4,224) Accrued interest (notes 10 and 14) 158,239 295,889 Foreign exchange loss 344,243 53,274 Accretion expenses (notes 8 and 10) 132,416 310,918 Financing costs (note 10) 1,004,182 - Non-cash working capital items: (64,831) (427,718) Accounts receivable and prepaid expenses (64,831) (427,718) Accounts payable and other liabilities 124,053 (422,474) Due to related parties (67,781) 168,784 Net cash and cash equivalents used in operating activities (67,781) (345,669) Exploration and evaluation assets (778,262) - Proceeds of private placements (note 11(b)(i)) 7,998,980 - Share issue costs (7783,262) - Proceeds of private placements (note 10) (23,802) (8,353) Net change in cash and cash equivalents 5,567,313)20	
Net loss for the period \$ (3,528,531) \$ (1,472,456) Adjustment for: Depreciation (note 6) 159,153 173,118 Stock-based compensation (note 11(d)) 1,235,141 (4,224) Accrued interest (notes 10 and 14) 158,239 295,889 Foreign exchange loss 344,243 53,274 Accretion expenses (notes 8 and 10) 132,416 310,918 Financing costs (note 10) 1,004,182 - Non-cash working capital items: (64,831) (427,718) Accounts receivable and prepaid expenses (64,831) (427,718) Accounts payable and other liabilities 124,053 (422,474) Due to related parties (67,781) 168,769 Purchase of property, plant and equipment (1,194,831) (345,669) Exploration and evaluation assets (783,262) - Proceeds of private placements (note 11(b)(i)) 7,998,980 - Share issue costs (783,262) - Proceeds of private placements (note 10) (23,802) (8,353) Net cash and cash equivalents 5,567,313 (1,709,	Operating activities					
Adjustment for: Depreciation (note 6) 159,153 173,118 Stock-based compensation (note 11(d)) 1,235,141 (4,224) Accrued interest (notes 10 and 14) 158,239 295,889 Foreign exchange loss 344,243 53,274 Accrued interest (notes 10 and 14) 132,416 310,918 Financing costs (note 10) 132,416 310,918 Non-cash working capital items: (427,718) (48,774) Accounts receivable and prepaid expenses (148,784) (427,718) Inventories (67,81) (48,784) (427,718) Accounts payable and other liabilities 124,053 (422,474) Due to related parties (67,81) (1,194,831) (345,669) Exploration and evaluation assets (1,194,831) (345,669) (402,788) Financing activities (1,282,287) (402,788) (402,788) Financing activities (783,262) (402,788) (402,788) Financing activities (783,262) (402,788) (402,788) (402,788) (402,788) Financing activities (783,262) (783,262) (783,262) (783,262)		\$	(3 528 531)	\$ (1 472	456)	
Depreciation (note 6) 159,153 173,118 Stock-based compensation (note 11(d)) 1,235,141 (4,224) Accrued interest (notes 10 and 14) 158,239 295,889 Foreign exchange loss 344,243 53,274 Accrued interest (notes 10 and 14) 132,416 310,918 Financing costs (note 10) 1,004,182 - Non-cash working capital items: (427,718) Accounts receivable and prepaid expenses (64,831) (427,718) Accounts payable and other liabilities 124,053 (422,474) Due to related parties (67,781) 168,784 Net cash and cash equivalents used in operating activities (67,781) (345,669) Exploration and evaluation assets (57,119) Investing activities (1,282,287) (402,788) - Purchase of property, plant and equipment (1,194,831) (345,669) - Share issue costs (783,262) - - Proceeds for private placements (note 11(b)(i)) 7,998,980 - - Share issue costs (783,262) - - -		Ψ	(0,020,001)	Ψ (1, 472	,400)	
Stock-based compensation (note 11(d)) 1,235,141 (4,224) Accrued interest (notes 10 and 14) 158,239 295,889 Foreign exchange loss 344,243 53,274 Accretion expenses (notes 8 and 10) 132,416 310,918 Financing costs (note 10) 1,004,182 - Non-cash working capital items: (64,831) (422,7718) Accounts receivable and prepaid expenses (168,600) 26,588 Inventories (64,831) (422,7718) Accounts payable and other liabilities (64,831) (422,7718) Accash and cash equivalents used in operating activities (67,781) 168,784 Net cash and cash equivalents used in operating activities (67,781) (1,298,301) Investing activities (87,456) (57,119) Purchase of property, plant and equipment (1,194,831) (345,669) Exploration and evaluation assets (87,456) (402,788) Financing activities (1,282,287) (402,788) Proceeds form exercise of warrants (783,262) - Proceeds from exercise of warrants (783,262) - Proceeds from exercise of warrants			159,153	173	.118	
Accrued interest (notes 10 and 14) 158,239 295,889 Foreign exchange loss 344,243 53,274 Accretion expenses (notes 8 and 10) 1,004,182 - Non-cash working capital items: 1,004,182 - Accounts receivable and prepaid expenses (168,600) 26,588 Inventories (64,831) (427,718) Accounts receivable and other liabilities 124,053 (422,474) Due to related parties (67,781) 168,784 Net cash and cash equivalents used in operating activities (67,781) 168,784 Purchase of property, plant and equipment (1,194,831) (345,669) Exploration and evaluation assets (87,456) (57,119) Net cash and cash equivalents used in investing activities (1,282,287) (402,788) Financing activities (783,262) - - Proceeds for private placements (note 11(b)(i)) 7,998,980 - - Share issue costs (783,262) - - Proceeds form exercise of warrants 330,000 - - Repayment of financing facilities (note 10) (23,802) (8,353) -						
Foreign exchange loss 344,243 53,274 Accretion expenses (notes 8 and 10) 132,416 310,918 Financing costs (note 10) 1,004,182 - Non-cash working capital items: 4ccounts receivable and prepaid expenses (168,600) 26,588 Inventories (422,1718) (422,1718) Accounts payable and other liabilities 124,053 (422,474) Due to related parties (67,781) 168,784 Net cash and cash equivalents used in operating activities (677,81) 168,784 Net cash and cash equivalents used in investing activities (1,194,831) (345,669) Purchase of property, plant and equipment (1,194,831) (345,669) Exploration and evaluation assets (87,456) (57,119) Net cash and cash equivalents used in investing activities (1,282,287) (402,788) Financing activities 7 (98,980 - Proceeds of private placements (note 11(b)(i)) 7,998,980 - - Share issue costs (783,262) - - Proceeds of private placements (note 11(b)(ii)) 7,998,980 - - Share issue costs						
Accretion expenses (notes 8 and 10) 132,416 310,918 Financing costs (note 10) 1,004,182 - Non-cash working capital items: (427,718) - Accounts receivable and prepaid expenses (168,600) 26,588 Inventories (64,831) (422,474) Accounts payable and other liabilities 124,053 (422,474) Due to related parties (67,781) 168,784 Net cash and cash equivalents used in operating activities (67,456) (57,119) Investing activities (1,194,831) (345,669) (22,278) Purchase of property, plant and equipment (1,194,831) (345,669) (22,278) Exploration and evaluation assets (67,456) (57,119) Net cash and cash equivalents used in investing activities (1,282,287) (402,788) Financing activities 7,598,980 - - Proceeds of private placements (note 11(b)(i)) 7,998,980 - - Share issue costs (783,262) - - - Proceeds from exercise of warrants 330,000 - - - Repayment of financing facilitites (n					,	
Financing costs (note 10) 1,004,182 - Non-cash working capital items: Accounts receivable and prepaid expenses (168,600) 26,588 Inventories (64,831) (427,718) Accounts payable and other liabilities 124,053 (422,474) Due to related parties (67,781) 168,784 Net cash and cash equivalents used in operating activities (67,781) 168,784 Net cash and cash equivalents used in operating activities (67,781) (345,669) Purchase of property, plant and equipment (1,194,831) (345,669) Exploration and evaluation assets (1,282,287) (402,788) Financing activities (1,282,287) (402,788) Proceeds of private placements (note 11(b)(i)) 7,989,980 - Share issue costs (783,262) - Proceeds form exercise of warrants 330,000 - Repayment of financing facilities (note 10) (23,802) (8,353) Net cash and cash equivalents 5,567,313 (1,709,442) Effect of exchange rate changes on cash held in foreign currencies (36,930) (4,025) Cash and cash equivalents, beginning of period 612,094 <td></td> <td></td> <td></td> <td></td> <td></td>						
Non-cash working capital items: Accounts receivable and prepaid expenses Inventories(168,600) (64,831)26,588 			1,004,182			
Accounts receivable and prepaid expenses(168,600)26,588Inventories(64,831)(427,718)Accounts payable and other liabilities124,053(422,474)Due to related parties(67,781)168,784Net cash and cash equivalents used in operating activities(67,216)(1,298,301)Investing activities(67,456)(57,119)Purchase of property, plant and equipment(1,194,831)(345,669)Exploration and evaluation assets(87,456)(57,119)Net cash and cash equivalents used in investing activities(1,282,287)(402,788)Financing activities(783,262)-Proceeds of private placements (note 11(b)(i))7,998,980-Share issue costs(783,262)-Proceeds from exercise of warrants330,000-Repayment of financing facilities (note 10)(23,802)(8,353)Net cash and cash equivalents5,567,313(1,709,442)Effect of exchange rate changes on cash held in foreign currencies(36,930)(4,025)Cash and cash equivalents, beginning of period612,0941,913,420Cash and cash equivalents, end of period\$ 6,142,477199,953Cash equivalents\$ 199,953-Cash equivalentsCash equivalents						
Accounts payable and other liabilities124,053(422,474)Due to related parties(67,781)168,784Net cash and cash equivalents used in operating activities(67,781)168,784Investing activities(672,316)(1,298,301)Purchase of property, plant and equipment(1,194,831)(345,669)Exploration and evaluation assets(87,456)(57,119)Net cash and cash equivalents used in investing activities(1,282,287)(402,788)Financing activities(783,262)-Proceeds of private placements (note 11(b)(i))7,998,980-Share issue costs(783,262)-Proceeds from exercise of warrants330,000-Repayment of financing facilities (note 10)(23,802)(8,353)Net cash and cash equivalents provided by (used in) financing activities7,521,916(8,353)Net change in cash and cash equivalents5,567,313(1,709,442)Effect of exchange rate changes on cash held in foreign currencies(36,930)(4,025)Cash and cash equivalents, beginning of period612,0941,913,420Cash equivalents, end of period\$ 6,142,477199,953Cash equivalentsCash equivalents			(168,600)	26	,588	
Due to related parties(67,781)168,784Net cash and cash equivalents used in operating activities(67,2316)(1,298,301)Investing activities(1,194,831)(345,669)Purchase of property, plant and equipment(1,194,831)(345,669)Exploration and evaluation assets(87,456)(57,119)Net cash and cash equivalents used in investing activities(1,282,287)(402,788)Financing activities(1,282,287)(402,788)Proceeds of private placements (note 11(b)(i))7,998,980-Share issue costs(783,262)-Proceeds from exercise of warrants330,000-Repayment of financing facilities (note 10)(23,802)(8,353)Net cash and cash equivalents provided by (used in) financing activities7,521,916(8,353)Net change in cash and cash equivalents5,567,313(1,709,442)Effect of exchange rate changes on cash held in foreign currencies(36,930)(4,025)Cash and cash equivalents, end of period§6,142,477§199,953Cash equivalentsCash equivalents	Inventories		(64,831)	(427	,718)	
Net cash and cash equivalents used in operating activities(672,316)(1,298,301)Investing activitiesPurchase of property, plant and equipment(1,194,831)(345,669)Exploration and evaluation assets(87,456)(57,119)Net cash and cash equivalents used in investing activities(1,282,287)(402,788)Financing activities(783,262)-Proceeds of private placements (note 11(b)(i))7,998,980-Share issue costs(783,262)-Proceeds from exercise of warrants330,000-Repayment of financing facilities (note 10)(23,802)(8,353)Net cash and cash equivalents provided by (used in) financing activities7,521,916(8,353)Net change in cash and cash equivalents5,567,313(1,709,442)Effect of exchange rate changes on cash held in foreign currencies(36,930)(4,025)Cash and cash equivalents, beginning of period612,0941,913,420Cash equivalents, end of period\$ 6,142,477199,953Cash equivalents	Accounts payable and other liabilities		124,053	(422	,474)	
Investing activitiesPurchase of property, plant and equipment(1,194,831)(345,669)Exploration and evaluation assets(87,456)(57,119)Net cash and cash equivalents used in investing activities(1,282,287)(402,788)Financing activities7,998,980-Proceeds of private placements (note 11(b)(i))7,998,980-Share issue costs(783,262)-Proceeds from exercise of warrants330,000-Repayment of financing facilities (note 10)(23,802)(8,353)Net cash and cash equivalents provided by (used in) financing activities7,521,916(8,353)Net change in cash and cash equivalents5,567,313(1,709,442)Effect of exchange rate changes on cash held in foreign currencies(36,930)(4,025)Cash and cash equivalents, beginning of period612,0941,913,420Cash and cash equivalents, end of period\$6,142,477\$Total2,0941,99,953-Cash equivalentsCash equivalentsCash equivalentsCash equivalentsCash equivalentsCash equivalentsCash equivalents	Due to related parties		(67,781)	168	,784	
Purchase of property, plant and equipment Exploration and evaluation assets(1,194,831) (87,456)(345,669) (57,119)Net cash and cash equivalents used in investing activities(1,282,287)(402,788)Financing activities Proceeds of private placements (note 11(b)(i))7,998,980 (783,262)-Share issue costs(783,262) (23,802)-Proceeds from exercise of warrants Repayment of financing facilities (note 10)(23,802) (8,353)(8,353)Net cash and cash equivalents provided by (used in) financing activities7,521,916(8,353)Net change in cash and cash equivalents5,567,313 (1,709,442)(1,709,442)Effect of exchange rate changes on cash held in foreign currencies(36,930) (4,025)(4,025)Cash and cash equivalents, beginning of period612,094 (1,913,4201,913,420Cash equivalents5,567,313 (1,90,953)199,953Cash equivalents5,142,477199,953	Net cash and cash equivalents used in operating activities		(672,316)	(1,298	,301)	
Purchase of property, plant and equipment Exploration and evaluation assets(1,194,831) (87,456)(345,669) (57,119)Net cash and cash equivalents used in investing activities(1,282,287)(402,788)Financing activities Proceeds of private placements (note 11(b)(i))7,998,980 (783,262)-Share issue costs(783,262) (23,802)-Proceeds from exercise of warrants Repayment of financing facilities (note 10)(23,802) (8,353)(8,353)Net cash and cash equivalents provided by (used in) financing activities7,521,916(8,353)Net change in cash and cash equivalents5,567,313 (1,709,442)(1,709,442)Effect of exchange rate changes on cash held in foreign currencies(36,930) (4,025)(4,025)Cash and cash equivalents, beginning of period612,094 (1,913,4201,913,420Cash equivalents5,567,313 (1,90,953)199,953Cash equivalents5,142,477199,953	Investing activities					
Exploration and evaluation assets(87,456)(57,119)Net cash and cash equivalents used in investing activities(1,282,287)(402,788)Financing activities7,998,980-Proceeds of private placements (note 11(b)(i))7,998,980-Share issue costs(783,262)-Proceeds from exercise of warrants330,000-Repayment of financing facilities (note 10)(23,802)(8,353)Net cash and cash equivalents provided by (used in) financing activities7,521,916(8,353)Net change in cash and cash equivalents5,567,313(1,709,442)Effect of exchange rate changes on cash held in foreign currencies(36,930)(4,025)Cash and cash equivalents, beginning of period612,0941,913,420Cash and cash equivalents, end of period\$ 6,142,477\$ 199,953Cash equivalents			(1 10/ 831)	(3/5	660)	
Net cash and cash equivalents used in investing activities(1,282,287)(402,788)Financing activitiesProceeds of private placements (note 11(b)(i))7,998,980-Share issue costs(783,262)-Proceeds from exercise of warrants330,000-Repayment of financing facilities (note 10)(23,802)(8,353)Net cash and cash equivalents provided by (used in) financing activities7,521,916(8,353)Net change in cash and cash equivalents5,567,313(1,709,442)Effect of exchange rate changes on cash held in foreign currencies(36,930)(4,025)Cash and cash equivalents, beginning of period612,0941,913,420Cash and cash equivalents, end of period\$ 6,142,477\$ 199,953Cash equivalents						
Financing activitiesProceeds of private placements (note 11(b)(i))7,998,980-Share issue costs(783,262)-Proceeds from exercise of warrants330,000-Repayment of financing facilities (note 10)(23,802)(8,353)Net cash and cash equivalents provided by (used in) financing activities7,521,916(8,353)Net change in cash and cash equivalents5,567,313(1,709,442)Effect of exchange rate changes on cash held in foreign currencies(36,930)(4,025)Cash and cash equivalents, beginning of period612,0941,913,420Cash and cash equivalents, end of period\$ 6,142,477\$ 199,953Cash equivalents						
Proceeds of private placements (note 11(b)(i))7,998,980-Share issue costs(783,262)-Proceeds from exercise of warrants330,000-Repayment of financing facilities (note 10)(23,802)(8,353)Net cash and cash equivalents provided by (used in) financing activities7,521,916(8,353)Net change in cash and cash equivalents5,567,313(1,709,442)Effect of exchange rate changes on cash held in foreign currencies(36,930)(4,025)Cash and cash equivalents, beginning of period612,0941,913,420Cash and cash equivalents, end of period\$ 6,142,477199,953Cash equivalents			(-,,,,	(10	<u>,</u>	
Share issue costs(783,262)-Proceeds from exercise of warrants330,000-Repayment of financing facilities (note 10)(23,802)(8,353)Net cash and cash equivalents provided by (used in) financing activities7,521,916(8,353)Net change in cash and cash equivalents5,567,313(1,709,442)Effect of exchange rate changes on cash held in foreign currencies(36,930)(4,025)Cash and cash equivalents, beginning of period612,0941,913,420Cash and cash equivalents, end of period\$ 6,142,477\$ 199,953Cash\$ 6,142,477\$ 199,953-Cash equivalents						
Proceeds from exercise of warrants330,000-Repayment of financing facilities (note 10)(23,802)(8,353)Net cash and cash equivalents provided by (used in) financing activities7,521,916(8,353)Net change in cash and cash equivalents5,567,313(1,709,442)Effect of exchange rate changes on cash held in foreign currencies(36,930)(4,025)Cash and cash equivalents, beginning of period612,0941,913,420Cash and cash equivalents, end of period\$ 6,142,477\$ 199,953Cash\$ 6,142,477\$ 199,953Cash equivalents				-		
Repayment of financing facilities (note 10)(23,802)(8,353)Net cash and cash equivalents provided by (used in) financing activities7,521,916(8,353)Net change in cash and cash equivalents5,567,313(1,709,442)Effect of exchange rate changes on cash held in foreign currencies(36,930)(4,025)Cash and cash equivalents, beginning of period612,0941,913,420Cash and cash equivalents, end of period\$ 6,142,477\$ 199,953Cash equivalents				-		
Net cash and cash equivalents provided by (used in) financing activities7,521,916(8,353)Net change in cash and cash equivalents5,567,313(1,709,442)Effect of exchange rate changes on cash held in foreign currencies(36,930)(4,025)Cash and cash equivalents, beginning of period612,0941,913,420Cash and cash equivalents, end of period\$ 6,142,477\$ 199,953Cash equivalents				-		
Net change in cash and cash equivalents5,567,313(1,709,442)Effect of exchange rate changes on cash held in foreign currencies(36,930)(4,025)Cash and cash equivalents, beginning of period612,0941,913,420Cash and cash equivalents, end of period\$ 6,142,477\$ 199,953Cash Cash equivalents					<i>,</i>	
Effect of exchange rate changes on cash held in foreign currencies(36,930)(4,025)Cash and cash equivalents, beginning of period612,0941,913,420Cash and cash equivalents, end of period\$ 6,142,477\$ 199,953Cash Cash equivalents\$ 199,953-	Net cash and cash equivalents provided by (used in) financing activities		7,521,916	(8	,353)	
Cash and cash equivalents, beginning of period612,0941,913,420Cash and cash equivalents, end of period\$ 6,142,477\$ 199,953Cash Cash equivalents\$ 6,142,477\$ 199,953	Net change in cash and cash equivalents		5,567,313	(1,709	,442)	
Cash and cash equivalents, end of period \$ 6,142,477 \$ 199,953 Cash \$ 6,142,477 \$ 199,953 Cash equivalents - -	Effect of exchange rate changes on cash held in foreign currencies		(36,930)	(4	,025)	
Cash \$ 6,142,477 \$ 199,953 Cash equivalents	Cash and cash equivalents, beginning of period		612,094	1,913	,420	
Cash equivalents	Cash and cash equivalents, end of period	\$	6,142,477	\$ 199	,953	
Cash equivalents						
	Cash	\$	6,142,477	\$ 199	,953	
Cash and cash equivalents \$ 6,142,477 \$ 199,953	Cash equivalents		-	-		
	Cash and cash equivalents	\$	6,142,477	\$,953	

The notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.



Galantas Gold Corporation Condensed Interim Consolidated Statements of Changes in Equity (Expressed in Canadian Dollars)

(Unaudited)

		_			Res	erv	es				
	Share capital		Warrants reserve	S	quity settled hare-based payments reserve		Foreign currency translation reserve	С	Equity mponent of onvertible lebenture	Deficit	Total
Balance, December 31, 2019	\$ 50,123,910	\$	786,000	\$	7,585,580	\$	796,754	\$	248,078	\$ (45,317,348)	\$ 14,222,974
Expiry of warrants	-		(786,000)		786,000		-		-	-	-
Stock-based compensation (note 11(d))	-		-		(4,224)		-		-	-	(4,224)
Exchange differences on translating											
foreign operations	-		-		-		(287,422)		-	-	(287,422)
Net loss for the period	-		-		-		-		-	(1,472,456)	(1,472,456)
Balance, June 30, 2020	\$ 50,123,910	\$	-	\$	8,367,356	\$	509,332	\$	248,078	\$ (46,789,804)	\$ 12,458,872
Balance, December 31, 2020	\$ 52,933,594	\$	340,000	\$	8,381,382	\$	1,012,739	\$		\$ (48,545,800)	\$ 14 121 915
Shares issued in private	Ψ 0 2 ,000,004	Ψ	040,000	Ψ	0,001,002	Ψ	1,012,700	Ψ		φ(+0,0+0,000)	ψ 14,121,010
placement (note 11(b)(i))	7,998,980		-		-		-		-	-	7,998,980
Warrants issued (note 11(b)(i))	(3,258,578)		3,258,578		-		-		-	-	-
Warrants issued (note 10(ii))	-		670,000		-		-		-	-	670,000
Share issue costs (note 11(b)(i))	(792,045)		8,783		-		-		-	-	(783,262)
Warrant extension (note 10(i))	-		251,000		-		-		-	-	251,000
Stock-based compensation (note 11(d))	-		-		1,235,141		-		-	-	1,235,141
Exercise of warrants	677,647		(347,647)		-		-		-	-	330,000
Exchange differences on translating			. ,								
foreign operations	-		-		-		(295,294)		-	-	(295,294)
Net loss for the period	-		-		-		-		-	(3,528,531)	(3,528,531)
Balance, June 30, 2021	\$ 57,559,598	\$	4,180,714	\$	9,616,523	\$	717,445	\$	-	\$(52,074,331)	\$ 19,999,949

The notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.



1. Going Concern

These unaudited condensed interim consolidated financial statements have been prepared on a going concern basis which contemplates that Galantas Gold Corporation (the "Company") will be able to realize assets and discharge liabilities in the normal course of business. In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future, which is at least, but is not limited to, twelve months from the end of the reporting period. Management is aware, in making its assessment, of uncertainties related to events or conditions that may cast doubt on the Company's ability to continue as a going concern. The Company's future viability depends on the consolidated results of the Company's wholly-owned subsidiary Cavanacaw Corporation ("Cavanacaw"). Cavanacaw has a 100% shareholding in both Flintridge Resources Limited ("Flintridge") who are engaged in the acquisition, exploration and development of gold properties, mainly in Omagh, Northern Ireland and Omagh Minerals Limited ("Omagh") who are engaged in the exploration of gold properties, mainly in the Republic of Ireland. The Omagh mine has an open pit mine, which was in production until 2013 when production was suspended and is reported as property, plant and equipment and as an underground mine which having established technical feasibility and commercial viability in December 2018 has resulted in associated exploration and evaluation assets being reclassified as an intangible development asset and reported as property, plant and equipment.

The going concern assumption is dependent upon forecast cash flows being met, further financing currently being negotiated. The directors assumptions in relation to future levels of production, gold prices and mine operating and capital costs are crucial to forecast cash flows being achieved. Should production be significantly delayed, revenues fall short of expectations or operating costs and capital costs increase significantly, there may be insufficient cash flows to sustain day to day operations without seeking further finance.

Negotiations with current finance providers to extend short-term loans have progressed positively and the maturity dates for both the G&F Phelps Ltd. ("G&F Phelps") and Ocean Partners loans have now been extended to December 31, 2023. The Company also raised gross proceeds of \$8M through the issuance of shares to new and current investors to meet the financial requirements of the Company for the foreseeable future. Based on the financial projections prepared, the directors believe it's appropriate to prepare the unaudited condensed interim consolidated financial statements on the going concern basis.

As at June 30, 2021, the Company had a deficit of \$52,074,331 (December 31, 2020 - \$48,545,800). Comprehensive loss for the six months ended June 30, 2021 was \$3,823,825 (six months ended June 30, 2020 - \$1,759,878). These conditions raise material uncertainties which may cast significant doubt as to whether the Company will be able to continue as a going concern. However, management is confident that it will continue as a going concern. However, this is subject to a number of factors including market conditions.

These unaudited condensed interim consolidated financial statements do not reflect adjustments to the carrying values of assets and liabilities, the reported expenses and financial position classifications used that would be necessary if the going concern assumption was not appropriate. These adjustments could be material.

2. Incorporation and Nature of Operations

The Company was formed on September 20, 1996 under the name Montemor Resources Inc. on the amalgamation of 1169479 Ontario Inc. and Consolidated Deer Creek Resources Limited. The name was changed to European Gold Resources Inc. by articles of amendment dated July 25, 1997. On May 5, 2004, the Company changed its name from European Gold Resources Inc. to Galantas Gold Corporation. The Company was incorporated to explore for and develop mineral resource properties, principally in Europe. In 1997, it purchased all of the shares of Omagh which owns a mineral property in Northern Ireland, including a delineated gold deposit. Omagh obtained full planning and environmental consents necessary to bring its property into production.



2. Incorporation and Nature of Operations (Continued)

The Company entered into an agreement on April 17, 2000, approved by shareholders on June 26, 2000, whereby Cavanacaw, a private Ontario corporation, acquired Omagh. Cavanacaw has established an open pit mine to extract the Company's gold deposit near Omagh, Northern Ireland. Cavanacaw also has developed a premium jewellery business founded on the gold produced under the name Galántas Irish Gold Limited ("Galántas"). As at July 1, 2007, the Company's Omagh mine began production and in 2013 production was suspended. On April 1, 2014, Galántas amalgamated its jewelry business with Omagh.

On April 8, 2014, Cavanacaw acquired Flintridge. Following a strategic review of its business by the Company during 2014 certain assets owned by Omagh were acquired by Flintridge.

On April 17, 2020, the Company completed a share consolidation of its share capital on the basis of ten existing common shares for one new common share consolidation.

The Company's operations include the consolidated results of Cavanacaw, and its wholly-owned subsidiaries Omagh, Galántas and Flintridge.

The Company's common shares are listed on the TSX Venture Exchange ("TSXV") and London Stock Exchange AIM under the symbol GAL. The primary office is located at The Canadian Venture Building, 82 Richmond Street East, Toronto, Ontario, Canada, M5C 1P1.

In March 2020, the World Health Organization declared coronavirus (COVID-19) a global pandemic. This contagious disease outbreak, which has continued to spread, has adversely affected workforces, economies, and financial markets globally, leading to an economic downturn. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company's business or ability to raise funds.

3. Basis of Preparation

Statement of compliance

The Company applies International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC"). These unaudited condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standard 34 - Interim Financial Reporting. Accordingly, they do not include all of the information required for full annual financial statements.

The policies applied in these unaudited condensed interim consolidated financial statements are based on IFRS issued and outstanding as of August 27, 2021 the date the Board of Directors approved the statements. The same accounting policies and methods of computation are followed in these unaudited condensed interim consolidated financial statements as compared with the most recent annual consolidated financial statements as at and for the year ended December 31, 2020. Any subsequent changes to IFRS that are given effect in the Company's annual consolidated financial statements for the year ending December 31, 2021 could result in restatement of these unaudited condensed interim consolidated financial statements.



Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended June 30, 2021 (Expressed in Canadian Dollars) (Unaudited)

4. Accounts Receivable and Prepaid Expenses

	As at June 30, 2021	De	As at cember 31, 2020
Sales tax receivable - Canada	\$ 11,877	\$	3,987
Valued added tax receivable - Northern Ireland	160,635		56,422
Accounts receivable	524,448		295,510
Prepaid expenses	54,168		239,041
	\$ 751,128	\$	594,960

Prepaid expenses includes advances for consumables and for construction of the passing bays in the Omagh mine.

The following is an aged analysis of receivables:

	As at June 30, 2021			
Less than 3 months 3 to 12 months	\$ 443,683 244,628	\$	120,085 117,615	
More than 12 months	244,626 8,649		118,219	
Total accounts receivable	\$ 696,960	\$	355,919	

5. Inventories

	As at June 30, 2021	As at December 31, 2020		
Concentrate inventories	\$ 143,858	\$	81,169	



Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended June 30, 2021 (Expressed in Canadian Dollars) (Unaudited)

6. **Property, Plant and Equipment**

Cost		Freehold land and buildings		Plant and machinery		Motor vehicles	•	Office quipment	D	evelopment assets (i)		Total
	\$		\$		\$		\$		¢		¢	
Balance, December 31, 2019 Additions	Ф	2,369,610	Ф	6,866,075 2,781	Ф	160,637	Ф	189,142	Ф	19,016,904 1,892,995	φ	28,602,368 1,895,776
Cash receipts from concentrate sales		-		2,701		-		-		(1,792,209)		
Foreign exchange adjustment		- 28,561		- 82,352		- 1,934		- 2,280		227,986		(1,792,209) 343,113
						,						
Balance, December 31, 2020 Additions		2,398,171		6,951,208		162,571		191,422		19,345,676		29,049,048
		- (35,184)		391,309 (101,486)		- (2,385)		- (2,808)		803,523 (282,338)		1,194,831
Foreign exchange adjustment	<u>ф</u>		•		•		<u>ф</u>	· · · ·		· · ·	•	(424,200)
Balance, June 30, 2021	\$	2,362,987	\$	7,241,031	\$	160,186	\$	188,614	\$	19,866,861	\$	29,819,679
		Freehold land and		Plant and		Motor		Office	D	evelopment		
Accumulated depreciation		buildings	I	machinery		vehicles	е	quipment		assets (i)		Total
Balance, December 31, 2019	\$	1,954,907	\$	5,259,569	\$	115,325	\$	112,851	\$	-	\$	7,442,652
Depreciation		7,910		322,574		13,252		11,460		-		355,196
Foreign exchange adjustment		23,644		66,443		1,530		1,480		-		93,097
Balance, December 31, 2020		1,986,461		5,648,586		130,107		125,791		-		7,890,945
Depreciation		3,106		146,390		4,846		4,811		-		159,153
Foreign exchange adjustment		(29,177)		(83,982)		(1,961)		(1,897)		-		(117,017)
Balance, June 30, 2021	\$	1,960,390	\$	5,710,994	\$	132,992	\$	128,705	\$	-	\$	7,933,081
		Freehold		Plant								
		I also all also all		and		Motor		Office	D	evelopment		
		land and								•		
Carrying value		land and buildings	I	machinery		vehicles	е	quipment		assets (i)		Total
Carrying value Balance, December 31, 2020	\$		\$		\$		е \$			•	\$	Total 21,158,103

(i) Development assets are expenditures for the underground mining operations in Omagh.



Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended June 30, 2021 (Expressed in Canadian Dollars) (Unaudited)

7. Exploration and Evaluation Assets

Cost	Exploration and evaluation assets
Balance, December 31, 2019	\$ 661,726
Additions	129,031
Impairment	(47,490)
Foreign exchange adjustment	7,474
Balance, December 31, 2020	750,741
Additions	87,456
Foreign exchange adjustment	(11,015)
Balance, June 30, 2021	\$ 827,182

Balance, December 31, 2020	\$ 750,741
Balance, June 30, 2021	\$ 827,182

8. Decommissioning Liability

The Company's decommissioning liability is a result of mining activities at the Omagh mine in Northern Ireland. The Company estimated its decommissioning liability at June 30, 2021 based on a risk-free discount rate of 1% (December 31, 2020 - 1%) and an inflation rate of 1.50% (December 31, 2020 - 1.50%). The expected undiscounted future obligations allowing for inflation are GBP 330,000 and based on management's best estimate the decommissioning is expected to occur over the next 5 to 10 years. On June 30, 2021, the estimated fair value of the liability is \$594,906 (December 31, 2020 - \$598,275). Changes in the provision during the six months ended June 30, 2021 are as follows:

	As at June 30, 2021	De	As at cember 31, 2020
Decommissioning liability, beginning of period Accretion	\$ 598,275 5,467 (8,826)	\$	580,303 10,863 7 100
Foreign exchange Decommissioning liability, end of period	\$ <u>(8,836)</u> 594,906	\$	7,109 598,275

As required by the Crown in Northern Ireland, the Company is required to provide a bond for reclamation related to the Omagh mine in the amount of GBP 300,000 (December 31, 2020 - GBP 300,000), of which GBP 300,000 was funded as of June 30, 2021 (GBP 300,000 was funded as of December 31, 2020) and reported as long-term deposit of \$513,780 (December 31, 2020 - \$521,430).



Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended June 30, 2021 (Expressed in Canadian Dollars) (Unaudited)

9. Accounts Payable and Other Liabilities

Accounts payable and other liabilities of the Company are principally comprised of amounts outstanding for purchases relating to exploration costs on exploration and evaluation assets, general operating activities and professional fees activities.

	As at June 30, 2021	De	As at ecember 31, 2020
Accounts payable	\$ 1,044,199	\$	423,630
Accrued liabilities	1,346,516		926,512
Total accounts payable and other liabilities	\$ 2,390,715	\$	1,350,142

The following is an aged analysis of the accounts payable and other liabilities:

	As at June 30, 2021	De	As at ecember 31, 2020
Less than 3 months	\$ 1,606,891	\$	432,946
3 to 12 months	106,806		76,800
12 to 24 months	5,515		161,327
More than 24 months	671,504		679,069
Total accounts payable and other liabilities	\$ 2,390,716	\$	1,350,142

10. Financing Facilities

Amounts payable on the Company's financial facilities are as follow:

	As at June 30, 2021	D	As at ecember 31, 2020
Financing facilities, beginning of period (i)	\$ 2,186,272	\$	1,440,185
Financing facility received (i)	-		262,460
Financing facility reallocated from due to related parties (ii)	4,578,039		-
Financing facility reallocated to due to related parties (i)	(2,577,137)		-
Less bonus warrants issued (i)	-		(340,000)
Less current portion	-		(2,186,272)
Repayment of financing facilities (i)	(23,802)		(49,705)
Accretion (i)	126,949		360,452
Interest (i)	86,820		214,377
Foreign exchange adjustment	224,333		298,503
Financing facilities - long term portion	\$ 4,601,474	\$	-



10. Financing Facilities (Continued)

(i) In April 2018, the Company signed a concentrate pre-payment agreement and loan facility for US\$1.6 million with a United Kingdom based company (the "Lender"), with a maturity date of December 31, 2020. The interest was set at US\$ 12 month LIBOR + 8.75% and payable monthly. No interest shall be charged for 6 months and repayments commenced against deliveries in 2019. There was a US\$25,000 arrangement fee.

In respect of the loan facility, a fixed and floating security, subordinated to an existing security to G&F Phelps, is being put in place over Flintridge assets. G&F Phelps has a first charge on Flintridge assets in respect of its loan facility and the Lender required an intercreditor agreement between G&F Phelps and the Lender.

As consideration for the loan facility, the United Kingdom based company received 1,500,000 bonus warrants of the Company. Each bonus warrant is exercisable into one common share of the Company and is subject to an initial four months plus one day hold period from the date of issuance of the bonus warrants. The bonus warrants have a maximum life of two years (the "Expiry Time"). On April 19, 2018, the 1,500,000 bonus warrants were granted. In the event that the weighted average closing price per common share of the Company is more than \$2.00 per share for more than five consecutive trading days, the Company shall be entitled to accelerate the Expiry Time to a date that is 30 days from the date on which the Company announces the accelerated Expiry Time by press release.

The fair value of the 1,500,000 bonus warrants was estimated at \$786,000 using the Black-Scholes option pricing model with the following assumptions: expected dividend yield - 0%, expected volatility - 113.55%, risk-free interest rate - 1.91% and an expected average life of 2 years.

On July 9, 2020, the Company amended the terms of its loan facility of an increase in the outstanding loan facility. The amount of the loan facility increased by US\$200,000 to a total of US\$1.8 million. On November 12, 2020, the additional US\$200,000 loan facility was drawn down by the Company. The interest rate applicable on the loan facility increased from US\$ 12 month LIBOR + 8.75% to US\$ 12 month LIBOR + 9.9% and the maturity date was extended from December 31, 2020 to December 31, 2021. Interest could be rolled into the loan facility until December 31, 2021, at the Company's option.

As consideration for amending the terms of the loan facility, the Lender received on August 14, 2020, 1,700,000 bonus warrants of Galantas ("Bonus Warrants"). Each Bonus Warrant will be exercisable for one common share of Galantas (a "Bonus Share") at an exercise price of \$0.33 per Bonus Share. The Bonus Warrants will expire on December 31, 2021 (the "Expiry Date") and the Bonus Shares will be subject to an initial four month plus one day hold period from the date of their issuance. In the event that the weighted average closing price per common share of the Company is more than \$0.4125 per share for more than five consecutive trading days, the Company shall be entitled to accelerate the Expiry Date to a date that is 30 days from the date on which the Company announces the accelerated Expiry Date by press release.

The fair value of the 1,700,000 bonus warrants was estimated at \$340,000 using the Black-Scholes option pricing model with the following assumptions: expected dividend yield - 0%, expected volatility - 165.75%, risk-free interest rate - 0.27% and an expected average life of 1.38 years.

The maturity date of the loan facility due on December 31, 2021 has been extended to December 31, 2023. Interest may be deferred and added to the balance outstanding until March 31, 2022, at which point interest will be paid monthly. The 1,700,000 Bonus Warrants issued have been extended.



10. Financing Facilities (Continued)

(i) (continued) The Company recorded the incremental difference of \$251,000 as financing costs based on the fair value of these warrants immediately prior to and after the modification. The fair value of the 1,700,000 Bonus Warrants was valued immediately prior to the subsequent extension using the following Black-Scholes option pricing model with the following assumptions: expected dividend yield - 0%, expected volatility - 123.98% to 144.48%, risk-free interest rate - 0.32% and an expected average life of 0.63 to 2.63 years.

This amendment to the loan facility is considered to be a modification of debt, accordingly, the fair value variances originated by the amendment of \$83,182 was immediately recorded under financing costs in the unaudited condensed interim consolidated statements of a loss.

During the three and six months ended June 30, 2021, the Company recorded accretion expense of \$25,145 and \$126,949, respectively in the unaudited condensed interim consolidated statements of loss in regards with this loan facility (year ended December 31, 2020 - \$360,452).

During the three and six months ended June 30, 2021, the Company recorded interest expense of \$39,660 and \$86,820, respectively in the unaudited condensed interim consolidated statements of loss in regards with this loan facility (year ended December 31, 2020 - \$214,377).

During the three and six months ended June 30, 2021, the Company recorded a repayment of \$nil and \$23,802, respectively in regards with this loan facility (year ended December 31, 2020 - \$49,705).

As at June 30, 2021, the Lender and the Company have a common director. As a result, the balance due to the Lender was reallocated from financing facilities to due to related parties. Total balance reallocated consisted of \$2,577,137. Refer to note 14(a)(iii).

(ii) In connection with the closing of the private placement completed on May 14, 2021 (refer to note 11(b)(i)), Roland Phelps has retired as the Company's President and Chief Executive Officer and as a member of the Board of Directors. As a result, the balance due to G&F Phelps, a company controlled by Roland Phelps was reallocated from due to related parties to financing facilities. Total balance reallocated consisted of \$3,163,593 (GBP 1,824,764) amalgamated loans balance and \$1,414,446 (GBP 815,854) interest accrued balance. Refer to note 14(a)(ii).

As at June 30, 2021, G&F Phelps had amalgamated loans to the Company of \$3,125,108 (GBP 1,824,774) (December 31, 2020 - \$3,171,622 - GBP 1,824,764) included with financing liabilities (December 31, 2020 - due to related parties) bearing interest at 2% above UK base rates, repayable on demand and secured by a mortgage debenture on all the Company's assets. In April 2018, the interest increased to 6.75% + US\$ 12 month LIBOR. Interest accrued on G&F Phelps loan is included with financing liabilities (December 31, 2020 - included with due to related parties). As at June 30, 2021, the amount of interest accrued is \$1,476,366 (GBP 862,061) (December 31, 2020 - \$1,339,503 - GBP 770,671).

The maturity date of the G&F Phelps loan has been extended to December 31, 2023. Interest may be deferred and added to the balance outstanding until March 31, 2022, at which point interest will be paid monthly. In consideration for extending the G&F loan and deferring interest, G&F Phelps has received, subject to regulatory approval, 1,700,000 warrants exercisable into one common share at an exercise price of \$0.33, with said warrants expiring on December 31, 2023.

The fair value of the 1,700,000 warrants was estimated at \$670,000 using the following Black-Scholes option pricing model with the following assumptions: expected dividend yield - 0%, expected volatility - 123.98% to 144.48%, risk-free interest rate - 0.32% and an expected average life of 2.63 years. The \$670,000 was recorded as financing costs in the unaudited condensed interim consolidated statements of a loss.



Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended June 30, 2021 (Expressed in Canadian Dollars) (Unaudited)

11. Share Capital and Reserves

a) Authorized share capital

At June 30, 2021, the authorized share capital consisted of an unlimited number of common and preference shares issuable in Series.

The common shares do not have a par value. All issued shares are fully paid.

No preference shares have been issued. The preference shares do not have a par value.

b) Common shares issued

At June 30, 2021, the issued share capital amounted to \$57,559,598. The continuity of issued share capital for the periods presented is as follows:

	Number of common shares	Amount
Balance, December 31, 2019 and June 30, 2020	32,321,472	\$ 50,123,910
Balance, December 31, 2020	46,565,537	\$ 52,933,594
Shares issued in private placement (i)	26,663,264	7,998,980
Warrants issued (i)	-	(3,258,578)
Share issue costs (i)	41,667	(792,045)
Exercise of warrants	1,000,000	677,647
Balance, June 30, 2021	74,270,468	\$ 57,559,598

(i) On May 14, 2021, Galantas completed a private placement of 26,663,264 units at a price of \$0.30 per unit for aggregate gross proceeds of \$7,998,980. Each unit comprises one common share and one common share purchase warrant. Each warrant will be exercisable into one additional common share at an exercise price of \$0.40 for 24 months from the closing date of the private placement. There is a four-month and one day hold period on the trading of securities issued in connection with this private placement.

The fair value of the 26,663,264 warrants was estimated at \$3,258,578 using the Black-Scholes option pricing model with the following assumptions: expected dividend yield - 0%, expected volatility - 155.08%, risk-free interest rate - 0.32% and an expected average life of 2 years.

Ocean Partners acquired 1,666,667 units of the private placement, for consideration of \$500,000 and the Company paid a finder's fee of 41,667 units to Ocean Partners resulting in the issuance of 1,708,334 common shares or 2.3% of the Company's issued and outstanding common shares on a non-diluted basis.

The 41,667 units paid as a finder's fee were valued at \$20,417. The fair value of the 41,667 warrants was estimated at \$8,783 using the Black-Scholes option pricing model with the following assumptions: expected dividend yield - 0%, expected volatility - 155.08%, risk-free interest rate - 0.32% and an expected average life of 2 years.



Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended June 30, 2021 (Expressed in Canadian Dollars) (Unaudited)

11. Share Capital and Reserves (Continued)

b) Common shares issued (Continued)

(i) (continued) Roland Phelps, the Company's retired President and Chief Executive Officer, acquired 166,667 units for consideration of \$50,000, increasing his holding to 5,100,484 common shares or 6.9% of the Company's issued and outstanding common shares on a non-diluted basis.

In respect of an under-writing by Ocean Partners, the Company paid a commitment fee of \$112,500 in cash.

c) Warrant reserve

The following table shows the continuity of warrants for the periods presented:

	Number of warrants	Weighted average exercise price
Balance, December 31, 2019 Expired	1,500,000 \$ (1,500,000)	1.58 1.58
Balance, June 30, 2020	- \$	-
Balance, December 31, 2020 Issued (notes 10(ii) and 11(b)(i))	1,700,000 \$ 28,404,931	0.33 0.40
Exercised	(1,000,000)	0.33
Balance, June 30, 2021	29,104,931 \$	0.39

The following table reflects the actual warrants issued and outstanding as of June 30, 2021:

Expiry date	Number of warrants	Grant date fair value (\$)	Exercise price (\$)
May 14, 2023	26,704,931	3,267,361	0.40
December 31, 2023	2,400,000	913,353	0.33
	29,104,931	4,180,714	0.39



147-1-1-4-1

Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended June 30, 2021 (Expressed in Canadian Dollars) (Unaudited)

11. Share Capital and Reserves (Continued)

d) Stock options

The following table shows the continuity of stock options for the periods presented:

	Number of options	Weighted average exercise price
Balance, December 31, 2019	1,395,000	\$ 0.92
Expired	(285,000)	1.05
Cancelled (iii)	(515,000)	1.01
Balance, June 30, 2020	595,000	\$ 1.15
Balance, December 31, 2020	570,000	\$ 1.16
Granted (i)(ii)	4,340,000	0.85
Balance, June 30, 2021	4,910,000	\$ 0.88

(i) On May 19, 2021, the Company granted 3,915,000 stock options to directors, employees and consultants of the Company to purchase common shares at \$0.86 per share until May 19, 2026. The options will vest as to one third immediately and one third on each of May 19, 2022 and May 19, 2023. The fair value attributed to these options was \$2,907,000 and was expensed in the unaudited condensed interim consolidated statements of loss and credited to equity settled share-based payments reserve. During the three and six months ended June 30, 2021, included in stock-based compensation is \$1,136,252 related to the vested portion of these options.

(ii) On June 21, 2021, the Company granted 425,000 stock options to consultants and officers of the Company to purchase common shares at \$0.73 per share until June 21, 2026. The options will vest as to one third immediately and one third on each of June 21, 2022 and June 21, 2023. The fair value attributed to these options was \$266,000 and was expensed in the unaudited condensed interim consolidated statements of loss and credited to equity settled sharebased payments reserve. During the three and six months ended June 30, 2021, included in stock-based compensation is \$91,946 related to the vested portion of these options.

(iii) The portion of the estimated fair value of options granted in the prior years and vested during the three and six months ended June 30, 2021, amounted to \$2,312 and \$6,943, respectively (three and six months ended June 30, 2020 - \$12,064 and \$53,286, respectively). In addition, during the three and six months ended June 30, 2021, nil options granted in the prior years were cancelled (three and six months ended June 30, 2020 - 515,000 options cancelled) and therefore, \$nil (three and six months ended June 30, 2020 - \$12,064 and \$57,510, respectively) of stock-based compensation was reversed related to the unvested portion of the options cancelled.



Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended June 30, 2021 (Expressed in Canadian Dollars) (Unaudited)

11. Share Capital and Reserves (Continued)

d) Stock options (continued)

The following table reflects the actual stock options issued and outstanding as of June 30, 2021:

Expiry date	Exercise price (\$)	Weighted average remaining contractual life (years)	Number of options outstanding	Number of options vested (exercisable)	Number of options unvested
March 25, 2022	1.35	0.73	320,000	320,000	-
April 19, 2023	1.10	1.80	25,000	25,000	-
February 13, 2024	0.90	2.62	125,000	125,000	-
June 27, 2024	0.90	2.99	100,000	100,000	-
May 19, 2026	0.86	4.89	3,915,000	1,305,000	2,610,000
June 21, 2026	0.73	4.98	425,000	141,667	283,333
	0.88	4.51	4,910,000	2,016,667	2,893,333

12. Net Loss per Common Share

The calculation of basic and diluted loss per share for the three and six months ended June 30, 2021 was based on the loss attributable to common shareholders of \$2,888,568 and \$3,528,531, respectively (three and six months ended June 30, 2020 - \$792,141 and \$1,472,456, respectively) and the weighted average number of common shares outstanding of 60,494,975 and 53,501,436, respectively (three and six months ended June 30, 2020 - 32,321,472 and 32,321,472, respectively) for basic and diluted loss per share. Diluted loss did not include the effect of 29,104,931 warrants (three and six months ended June 30, 2020 - nil) and 4,910,000 options (three and six months ended June 30, 2020 - 595,000) for the three and six months ended June 30, 2021, as they are anti-dilutive.

13. Revenues

Shipments of concentrate under the off-take arrangements commenced during the second quarter of 2019. Concentrate sales provisional revenues during the three and six months ended June 30, 2021 totaled approximately US\$218,000 and US\$785,000, respectively (three and six months ended June 30, 2020 - US\$nil and US\$186,000, respectively). However, until the mine reaches the commencement of commercial production, the net proceeds from concentrate sales will be offset against Development assets.



Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended June 30, 2021 (Expressed in Canadian Dollars) (Unaudited)

14. Related Party Disclosures

Related parties include the Board of Directors, close family members, other key management individuals and enterprises that are controlled by these individuals as well as certain persons performing similar functions.

Related party transactions conducted in the normal course of operations are measured at the fair value and approved by the Board of Directors in strict adherence to conflict of interest laws and regulations.

(a) The Company entered into the following transactions with related parties:

		Three Mo Jun	nths 1e 30		Six Months June 3	
	Note	2021		2020	2021	2020
Interest on related party loans	(i)	\$ 39,660	\$	79,872	\$ 118,536 \$	166,405

(i) Refer to note 10(i)(ii).

(ii) Refer to note 11(b)(i).

(iii) As at June 30, 2021, the Lender and the Company have a common director. As a result, the balance due to the Lender was reallocated from financing facilities to due to related parties. Total balance reallocated consisted of \$2,577,137. Refer to note 10(i).

(b) Remuneration of officer and directors of the Company was as follows:

	Three Months Ended June 30,		Six Months Ended June 30,			
		2021	2020		2021	2020
Salaries and benefits ⁽¹⁾	\$	50,380	\$ 117,228	\$	167,986 \$	231,727
Stock-based compensation		828,180	6,412		830,438	15,726
	\$	878,560	\$ 123,640	\$	998,424 \$	247,453

⁽¹⁾ Salaries and benefits include director fees. As at June 30, 2021, due to directors for fees amounted to \$64,250 (December 31, 2020 - \$126,536) and due to officers, mainly for salaries and benefits accrued amounted to \$36,592 (December 31, 2020 - \$782,145 - GBP 458,701), and is included with due to related parties.

(c) As of June 30, 2021, Ross Beaty owns 3,744,747 common shares of the Company or approximately 5.04% of the outstanding common shares. Roland Phelps, former Chief Executive Officer and former director, owns, directly and indirectly, 5,100,484 common shares of the Company or approximately 6.87% of the outstanding common shares of the Company. Premier Miton owns 4,848,243 common shares of the Company or approximately 6.53%. Melquart owns, directly and indirectly, 23,073,528 common shares of the Company or approximately 31.07% of the outstanding common shares of the Company. Eric Sprott owns 6,333,333 common shares of the Company or approximately 8.53%. Mike Gentile owns 4,000,000 common shares of the Company or approximately 5.39%. The remaining 36.57% of the shares are widely held, which includes various small holdings which are owned by directors of the Company. These holdings can change at anytime at the discretion of the owner.

The Company is not aware of any arrangements that may at a subsequent date result in a change in control of the Company.



15. Segment Disclosure

The Company has determined that it has one reportable segment. The Company's operations are substantially all related to its investment in Cavanacaw and its subsidiaries, Omagh and Flintridge. Substantially all of the Company's revenues, costs and assets of the business that support these operations are derived or located in Northern Ireland. Segmented information on a geographic basis is as follows:

June 30, 2021	United Kingdom Canada Total
Current assets	\$ 1,072,639 \$ 5,964,824 \$ 7,037,463
Non-current assets	\$ 23,170,402 \$ 57,158 \$ 23,227,560
Revenues	\$ - \$ - \$ -
December 31, 2020	United Kingdom Canada Total
December 31, 2020 Current assets	United Kingdom Canada Total \$ 1,232,744 \$ 55,479 \$ 1,288,223
	•

16. Contingency

During the year ended December 31, 2010, the Company's subsidiary Omagh received a payment demand from Her Majesty's Revenue and Customs ("HMRC") in the amount of \$521,127 (GBP 304,290) in connection with an aggregate levy arising from the removal of waste rock from the mine site during 2008 and early 2009. Omagh Minerals believed this claim to be without merit. An appeal was lodged with the Tax Tribunals Service and the hearing started at the beginning of March 2017 and following a number of adjournments was completed in August 2018. During the year ended December 31, 2019, the Tax Tribunals Service issued their judgement dismissing the appeal by Omagh in respect of the assessments. A provision has now been included in the unaudited condensed interim consolidated financial statements in respect of the aggregates levy plus interest and penalty.

There is a contingent liability in respect of potential additional interest which may be applied in respect of the aggregates levy dispute. Omagh is unable to make a reliable estimate of the amount of the potential additional interest that may be applied by HMRC.

17. Events After the Reporting Period

On July 26, 2021, the Company announced that it has retained Independent Trading Group ("ITG") to provide market making services in accordance with TSXV policies.

ITG will trade the securities of Galantas on the TSXV for the purposes of maintaining an orderly market. In consideration of the services provided by ITG, the Company will pay ITG a monthly cash fee of \$5,000 for a minimum term of three months and renewable thereafter. Galantas and ITG are unrelated and unaffiliated entities. ITG will not receive shares or options as compensation. The capital used for market making will be provided by ITG.

